Novo Nordisk's Ozempic Potentially Linked To Rare Vision Loss Risk, But Absolute Risk Is Low: Study
Semaglutide use in diabetes patients is linked to a higher risk of NAION, a rare eye condition. A Danish-Norwegian study ...
Ozempic Works on Kidney Disease, Regulator Says. Why Novo Nordisk Stock Is Falling.
Novo Nordisk’s blockbuster drug Ozempic got another star added to its label Thursday, in an encouraging sign for the ...
FiercePharma8h
Novo Nordisk’s chief scientific officer looks to the future of GLP-1s
GLP-1 agonists have taken the pharma world by storm, and Novo Nordisk has been at the forefront of it all thanks to ...
American Century Focused Global Growth Fund Q3 2024 Commentary
Stocks rebounded from a brief early August downturn fed by fears the Fed wouldn’t act quickly enough to stave off a recession ...
Danish Court Sentences British Hedge Fund Trader to 12 Years Over Massive Tax Fraud
A Danish court has sentenced a British hedge fund trader to 12 years in prison in connection with what authorities say was a 9 billion kroner ($1.3 billion) tax fraud, Danish justice officials confirm ...
Business Insider11h
Study confirms semaglutide link to increased, but ‘low,’ risk of NAION
Novo Nordisk’s (NVO) semaglutide is a GLP-1 weight loss drug marketed as three separate brand name medications, Ozempic, Wegovy, and Rybelsus. Novo’s Wegovy competes with Eli Lilly’s (LLY) Zepbound.
Business Insider15h
Novo Nordisk’s Ozempic® Gains EMA Positive Opinion for Kidney Disease Risk Reduction
Pick the best stocks and maximize your portfolio: Novo Nordisk ( (NVO)) has provided an update. Novo Nordisk announced that the European Medicines Agency’s Committee for Medicinal Products for Human ...